Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors.

abstract：:Despite availability of biologic therapies, limited patient access to many of the most-effective cancer treatments affects overall health outcomes. To address this issue, many governments have enacted legislation for the approval of biosimilars. The term "biosimilar" refers to a biologic product that is developed to b...

journal_title：mAbs

authors： Socinski MA,Curigliano G,Jacobs I,Gumbiner B,MacDonald J,Thomas D

更新日期：2015-01-01 00:00:00

abstract：:Gel microdroplet - fluorescence activated cell sorting (GMD-FACS) is an innovative high throughput screening platform for recombinant protein libraries, and we show here that GMD-FACS can overcome many of the limitations associated with conventional screening methods for antibody libraries. For example, phage and cell...

journal_title：mAbs

authors： Fang Y,Chu TH,Ackerman ME,Griswold KE

更新日期：2017-11-01 00:00:00

abstract：:The Fc glycosylation of therapeutic antibodies is crucial for their effector functions and their behavior in pharmacokinetics and pharmacodynamics. To monitor the Fc glycosylation in bioprocess development and characterization,high-throughput techniques for glycosylation analysis are needed. Here, we describe the deve...

journal_title：mAbs

authors： Reusch D,Haberger M,Kailich T,Heidenreich AK,Kampe M,Bulau P,Wuhrer M

更新日期：2014-01-01 00:00:00

abstract：:Monoclonal antibodies (mAb) have become a mainstay in tumor therapy. Clinical responses to mAb therapy, however, are far from optimal, with many patients presenting native or acquired resistance or suboptimal responses to a mAb therapy. MAbs exert antitumor activity through different mechanisms of action and we propos...

journal_title：mAbs

authors： Marcucci F,Bellone M,Rumio C,Corti A

更新日期：2013-01-01 00:00:00

abstract：:Antibody-drug conjugates (ADCs) represent a new class of cancer therapeutics. Their design involves a tumor-specific antibody, a linker and a cytotoxic payload. They were designed to allow specific targeting of highly potent cytotoxic agents to tumor cells whilst sparing normal cells. Frequent toxicities that may be d...

journal_title：mAbs

authors： Donaghy H

更新日期：2016-05-01 00:00:00

abstract：:Genomic studies have been revolutionized by the use of next generation sequencing (NGS) that delivers huge amounts of sequence information in a short span of time. The number of applications for NGS is rapidly expanding and significantly transforming many areas of life sciences. The field of antibody research and disc...

journal_title：mAbs

authors： Fischer N

更新日期：2011-01-01 00:00:00

abstract：:One aspiration for the formulation of human monoclonal antibodies (mAb) is to reach high solution concentrations without compromising stability. Protein surface activity leading to instability is well known, but our understanding of mAb adsorption to the solid-liquid interface in relevant pH and surfactant conditions ...

journal_title：mAbs

authors： Couston RG,Skoda MW,Uddin S,van der Walle CF

更新日期：2013-01-01 00:00:00

abstract：:Glycosylation is a critical attribute for development and manufacturing of therapeutic monoclonal antibodies (mAbs) in the pharmaceutical industry. Conventional antibody glycan analysis is usually achieved by the 2-aminobenzamide (2-AB) hydrophilic interaction liquid chromatography (HILIC) method following the release...

journal_title：mAbs

authors： Yang X,Kim SM,Ruzanski R,Chen Y,Moses S,Ling WL,Li X,Wang SC,Li H,Ambrogelly A,Richardson D,Shameem M

更新日期：2016-05-01 00:00:00

abstract：:The cervical mucosa of women who are highly exposed to HIV-1, yet remain persistently seronegative (HEPS), presents a unique opportunity to study the dynamics of an immune compartment potentially capable of preventing HIV-1 infection. Herein, we provide a detailed characterization of the immunoglobulin repertoire of c...

journal_title：mAbs

authors： Gaudet RG,Breden F,Plummer F,Berry JD

更新日期：2011-03-01 00:00:00

abstract：:Glycosylation is an important post-translational modification during protein production in eukaryotic cells, and it is essential for protein structure, stability, half-life, and biological functions. In this study, we produced various monoclonal antibody (mAb) glycoforms from Chinese hamster ovary (CHO) cells, includi...

journal_title：mAbs

authors： Zheng K,Yarmarkovich M,Bantog C,Bayer R,Patapoff TW

更新日期：2014-05-01 00:00:00

abstract：:A mono-specific antibody may recruit a second antigen binding specificity, thus converting to a dual-specific Two-in-One antibody through mutation at the light chain complementarity-determining regions (CDRs). It is, however, unknown whether mutation at the heavy chain CDRs may evolve such dual specificity. Herein, we...

journal_title：mAbs

authors： Lee CV,Koenig P,Fuh G

更新日期：2014-05-01 00:00:00

abstract：:Interactions between the cytoplasmic domains of viral transmembrane proteins and host machinery often determine the outcome of viral infection. The M2 protein of influenza A has been identified as a key player in autophagy-mediated viral replication. Here, we describe the engineering and validation of an antibody spec...

journal_title：mAbs

authors： Velappan N,Micheva-Viteva S,Adikari SH,Waldo GS,Lillo AM,Bradbury ARM

更新日期：2020-01-01 00:00:00

abstract：:Monoclonal antibodies (mAbs) are a burgeoning class of therapeutics, with more than 25 approved in countries worldwide. Novel molecules are entering clinical study at a rate of nearly 40 per year, and the commercial pipeline includes approximately 240 mAb therapeutics in clinical studies that have not yet progressed t...

journal_title：mAbs

authors： Reichert JM

更新日期：2010-01-01 00:00:00

abstract：:We describe here the identification of a stop codon TAA (Stop) → GAA (Glu) = Stop221E mutation on the light chain of a recombinant IgG1 antibody expressed in a Chinese hamster ovary (CHO) cell line. The extended light chain variants, which were caused by translation beyond the mutated stop codon to the next alternativ...

journal_title：mAbs

authors： Zhang T,Huang Y,Chamberlain S,Romeo T,Zhu-Shimoni J,Hewitt D,Zhu M,Katta V,Mauger B,Kao YH

更新日期：2012-11-01 00:00:00

abstract：:Ang1 is a soluble ligand to receptor Tie2, and increasing the circulating Ang1 level may improve vascular stabilization under certain disease conditions. Here, we found that the circulating Ang1 level was significantly increased in cynomolgus monkeys treated with non-neutralizing anti-Ang1 antibodies. Improving the an...

journal_title：mAbs

authors： Zheng C,Toth J,Bigwarfe T,MacDougall M,Jerath K,Bovat K,Smith J,Sun P,Hayes D,Fryer R,Singh S,Kroe-Barrett R

更新日期：2018-11-01 00:00:00

abstract：:The critical role played by IgE in allergic asthma is well-documented and clinically precedented, but some patients in whom IgE neutralization may still offer clinical benefit are excluded from treatment with the existing anti-IgE therapy, omalizumab, due to high total IgE levels or body mass. In this study, we sought...

journal_title：mAbs

authors： Cohen ES,Dobson CL,Käck H,Wang B,Sims DA,Lloyd CO,England E,Rees DG,Guo H,Karagiannis SN,O'Brien S,Persdotter S,Ekdahl H,Butler R,Keyes F,Oakley S,Carlsson M,Briend E,Wilkinson T,Anderson IK,Monk PD,von Wachenfe

更新日期：2014-05-01 00:00:00

abstract：:Tremendous knowledge has been gained in the understanding of various modifications of IgG antibodies, driven mainly by the fact that antibodies are one of the most important groups of therapeutic molecules and because of the development of advanced analytical techniques. Recombinant monoclonal antibody (mAb) therapeut...

journal_title：mAbs

authors： Liu H,Ponniah G,Zhang HM,Nowak C,Neill A,Gonzalez-Lopez N,Patel R,Cheng G,Kita AZ,Andrien B

更新日期：2014-01-01 00:00:00

abstract：:Antibodies that target a clinically relevant group of receptors within the tumor necrosis factor receptor superfamily (TNFRSF), including CD40 and CD95 (Fas/Apo-1), also require binding to Fc gamma receptors (FcγRs) to elicit a strong agonistic activity. This FcγR dependency largely relies on the mere cellular anchori...

journal_title：mAbs

authors： Nelke J,Medler J,Weisenberger D,Beilhack A,Wajant H

更新日期：2020-01-01 00:00:00

abstract：:Patents provide one of the few protections companies can avail themselves of to help protect their therapeutic monoclonal antibody products. Just as the therapeutic monoclonal antibody field is constantly evolving, so too is the legal environment surrounding these inventions. In a series of articles, the general state...

journal_title：mAbs

authors： McCabe KW

更新日期：2009-07-01 00:00:00

abstract：:Fusion proteins combining oligomeric assemblies of a genetically obtained single-chain (sc) variant of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) with antibodies directed against tumor-associated antigens represent a promising strategy to overcome the limited therapeutic activity of conventional s...

journal_title：mAbs

authors： Siegemund M,Seifert O,Zarani M,Džinić T,De Leo V,Göttsch D,Münkel S,Hutt M,Pfizenmaier K,Kontermann RE

更新日期：2016-07-01 00:00:00

abstract：:In recent years, capillary electrophoresis-sodium dodecyl sulfate (cSDS) has been widely used for high resolution separation and quantification of the fragments and aggregates of monoclonal antibodies (mAbs) to ensure the quality of mAb therapeutics. However, identification of the low-molecular-weight (LMW) and high-m...

journal_title：mAbs

authors： Wang WH,Cheung-Lau J,Chen Y,Lewis M,Tang QM

更新日期：2019-10-01 00:00:00

abstract：:Biological therapies have revolutionized the treatment of several cancers and systemic immune-mediated inflammatory conditions. Expiry of patents protecting a number of biologics has provided the opportunity to commercialize highly similar versions, known as biosimilars. Biosimilars are approved by regulatory agencies...

journal_title：mAbs

authors： Scheinberg M,Pineda C,Castañeda-Hernández G,Zarbá JJ,Damião A,Arantes LH Jr,Jacobs I

更新日期：2018-08-01 00:00:00

abstract：:Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or TRAIL-receptor agonistic monoclonal antibodies promote apoptosis in most cancer cells, and the differential expression of TRAIL-R2 between tumor and normal tissues allows its exploitation as a tumor-associated antigen. The use of thes...

journal_title：mAbs

authors： Satta A,Mezzanzanica D,Caroli F,Frigerio B,Di Nicola M,Kontermann RE,Iacovelli F,Desideri A,Anichini A,Canevari S,Gianni AM,Figini M

更新日期：2018-10-01 00:00:00

abstract：:Therapeutic monoclonal antibodies (mAbs) are highly complex proteins that must be exhaustively characterized according to the regulatory authorities' recommendations. MAbs display micro-heterogeneity mainly due to their post-translational modifications, but also to their susceptibility to chemical and physical degrada...

journal_title：mAbs

authors： Rouby G,Tran NT,Leblanc Y,Taverna M,Bihoreau N

更新日期：2020-01-01 00:00:00

abstract：:Monomeric IgA has been proposed as an alternative antibody format for cancer therapy. Here, we present our studies on the production, purification and functional evaluation of anti-HER2 IgA antibodies as anti-cancer agents in comparison to the anti-HER2 IgG1 trastuzumab. MALDI-TOF MS analysis showed profound differenc...

journal_title：mAbs

authors： Rouwendal GJ,van der Lee MM,Meyer S,Reiding KR,Schouten J,de Roo G,Egging DF,Leusen JH,Boross P,Wuhrer M,Verheijden GF,Dokter WH,Timmers M,Ubink R

更新日期：2016-01-01 00:00:00

abstract：:Although extensively studied, protein-protein interactions remain highly elusive and are of increasing interest in drug development. We show the assembly of a monoclonal antibody, using multivalent carboxylate ions, into highly-ordered structures. While the presence and function of similar structures in vivo are not k...

journal_title：mAbs

authors： Esue O,Xie AX,Kamerzell TJ,Patapoff TW

更新日期：2013-03-01 00:00:00

abstract：:Recombinant antibody single-chain variable fragments (scFv) are difficult to purify homogeneously from a protein complex mixture. The most effective, specific and fastest method of purification is an affinity chromatography on Protein L (PpL) matrix. This protein is a multi-domain bacterial surface protein that is abl...

journal_title：mAbs

authors： Lakhrif Z,Pugnière M,Henriquet C,di Tommaso A,Dimier-Poisson I,Billiald P,Juste MO,Aubrey N

更新日期：2016-01-01 00:00:00

abstract：:Post-translational modifications can have a signification effect on antibody stability. A comprehensive approach is often required to best understand the underlying reasons the modification affects the antibody's potency or aggregation state. Monoclonal antibody 001 displayed significant variation in terms of potency,...

journal_title：mAbs

authors： McSherry T,McSherry J,Ozaeta P,Longenecker K,Ramsay C,Fishpaugh J,Allen S

更新日期：2016-05-01 00:00:00

abstract：:Therapeutic monoclonal antibodies (mAbs) currently dominate the biologics marketplace. Development of a new therapeutic mAb candidate is a complex, multistep process and early stages of development typically begin in an academic research environment. Recently, a number of facilities and initiatives have been launched ...

journal_title：mAbs

authors： Munro TP,Mahler SM,Huang EP,Chin DY,Gray PP

更新日期：2011-09-01 00:00:00

abstract：:The epidermal growth factor receptor (EGFR) is frequently dysregulated in human malignancies and a validated target for cancer therapy. Two monoclonal anti-EGFR antibodies (cetuximab and panitumumab) are approved for clinical use. However, the percentage of patients responding to treatment is low and many patients exp...

journal_title：mAbs

authors： Koefoed K,Steinaa L,Søderberg JN,Kjær I,Jacobsen HJ,Meijer PJ,Haurum JS,Jensen A,Kragh M,Andersen PS,Pedersen MW

更新日期：2011-11-01 00:00:00